Pharmacokinetics of guanfacine in patients undergoing haemodialysis
暂无分享,去创建一个
[1] A. Jäättelä. Clinical efficacy of BS 100-141 in essential hypertension , 2004, European Journal of Clinical Pharmacology.
[2] P. Jerie,et al. Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy. , 1981, International journal of clinical pharmacology, therapy, and toxicology.
[3] W. Braun,et al. The Influence of Renal Function on Plasma Concentration, Urinary Excretion and, Antihypertensive Effect of Guanfacine , 1980, Clinical pharmacokinetics.
[4] Y. Seedat. Long-term treatment of hypertension with guanfacine alone and in combination therapy. , 1980, British journal of clinical pharmacology.
[5] W. Braun,et al. Elimination of guanfacine in patients with normal and impaired renal function. , 1980, British journal of clinical pharmacology.
[6] J. Kiechel. Pharmacokinetics and metabolism of guanfacine in man: a review. , 1980, British journal of clinical pharmacology.
[7] W. Kirch,et al. Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. , 1978, International journal of clinical pharmacology and biopharmacy.
[8] G. Scholtysik,et al. Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141). , 1975, Arzneimittel-Forschung.
[9] G. Scholtysik,et al. Substituted phenylacetylguanidines: a new class of antihypertensive agents. , 1975, Arzneimittel-Forschung.